Bendamustine

Bendamustine
Clinical data
Trade names	Treanda, others
Other names	SDX-105
AHFS/Drugs.com	Monograph
MedlinePlus	a608034
License data	US DailyMed: Treanda;
Routes of; administration	Intravenous infusion
ATC code	L01AA09 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	NA (intravenous only)
Protein binding	94–96%
Metabolism	Hydrolyzed to inactive metabolites. Two minor metabolites (M3 and M4) formed by CYP1A2
Elimination half-life	40 min (bendamustine), 3 h (M3), 30 min (M4)
Excretion	~50% urinary, ~25% fecal
Identifiers
	IUPAC name 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;
CAS Number	16506-27-7 ;
PubChem CID	65628;
IUPHAR/BPS	7478;
DrugBank	DB06769 ;
ChemSpider	59069 ;
UNII	9266D9P3PQ;
ChEMBL	ChEMBL487253 ;
CompTox Dashboard (EPA)	DTXSID2046888 ;
ECHA InfoCard	100.205.789
Chemical and physical data
Formula	C16H21Cl2N3O2
Molar mass	358.26 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES ClCCN(c2ccc1c(nc(n1C)CCCC(=O)O)c2)CCCl;
	InChI InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23) ; Key:YTKUWDBFDASYHO-UHFFFAOYSA-N ;
	(verify)

Bendamustine, sold under the brand name Treanda among others, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.

Common side effects include low blood cell counts, fever, nausea, diarrhea, loss of appetite, cough, and rash. Other severe side effects include allergic reactions and increased risk of infection. Use in pregnancy is known to harm the baby. Bendamustine is in the alkylating agents family of medication. It works by interfering with the function of DNA and RNA.

Bendamustine was approved for medical use in the United States in 2008. It is on the World Health Organization's List of Essential Medicines. It was originally made from nitrogen mustard.